Multinational pharmaceutical companies are shifting strategies in China, focusing on partnerships with local biotech firms to leverage innovation and growth potential.
Key facts
- •Multinational pharmaceutical firms are moving away from asset-heavy operations in China.
- •AstraZeneca and CSPC Pharmaceutical Group are building a new manufacturing site in Shijiazhuang.
- •AstraZeneca holds a 49 percent stake in its new joint venture with CSPC.
- •Mölnlycke partnered with Zhende Medical in May to co-develop surgical and wound care products.
- •The Global Health Summit concluded in Hong Kong on Saturday.
Global pharmaceutical companies are increasingly investing in China’s biotech sector to capitalize on valuation growth and innovation. Speakers at the Global Health Summit in Hong Kong noted that multinational firms are moving away from asset-heavy operations in China in favor of deeper integration with local partners.
Strategic Shift Toward Innovation
Xu Chenming, head of the healthcare group at Citic Securities, stated that multinational pharmaceutical companies are prioritizing investments in firms with strong innovation capabilities. This shift is intended to foster growth for Chinese companies and enhance their ability to compete globally.
Recent Joint Ventures
AstraZeneca announced a joint venture with CSPC Pharmaceutical Group on Wednesday to establish a drug manufacturing site in Shijiazhuang, Hebei province. AstraZeneca will hold a 49 percent stake in the venture, which will initially focus on manufacturing and supplying products for the global market. Additionally, in May, the Swedish firm Mölnlycke formed a joint venture with Zhende Medical, based in Zhejiang province, to co-develop products and combine business portfolios.
Timeline
- MayMölnlycke formed a joint venture with Zhende Medical.
- WednesdayAstraZeneca announced a joint venture with CSPC Pharmaceutical Group.
- SaturdayThe Global Health Summit concluded in Hong Kong.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by SCMP Business.
